Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574064 | 0.81 | ALDH1A1 (0.46) | KDM1AALDH1A1TP53MAOBSIGMAR1 | |
| SCHEMBL412891 | 0.76 | KDM1A (0.48) | KDM1AALDH1A1TP53MAOBTSHR | |
| SCHEMBL27908726 | 0.76 | KDM1A (0.48) | KDM1AALDH1A1TP53MAOBTSHR | |
| SCHEMBL29529565 | 0.76 | KDM1A (0.48) | KDM1AALDH1A1TP53MAOBTSHR | |
| Ammonia Solution, Strong SCHEMBL27832849 | 0.74 | KDM1A (0.47) | KDM1AALDH1A1TP53MAOBTSHR | |
| Hydrochloric Acid SCHEMBL27330764 | 0.74 | KDM1A (0.47) | KDM1AALDH1A1TP53MAOBSIGMAR1 | |
| SCHEMBL25068935 | 0.73 | KDM1A (0.47) | KDM1AMAOBTSHRTDP1HTR2A | |
| Hydrochloric Acid SCHEMBL30124100 | 0.73 | KDM1A (0.47) | KDM1AALDH1A1TP53MAOBSIGMAR1 | |
| SCHEMBL2464182 | 0.72 | KDM1A (0.55) | KDM1AALDH1A1TP53MAOBSIGMAR1 | |
| SCHEMBL7441079 | 0.72 | KDM1A (0.55) | KDM1AALDH1A1TP53MAOBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| EP-3328835-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2022-10-12 | — | — | EP | disclosed |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20200383993-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10624900-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20200078368-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| US-10272094-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180214455-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624900-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | KDM1A 1318/4885ALDH1A1 1924/4885TP53 4860/4885 |
| US-20180214455-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | KDM1A 1318/4885ALDH1A1 1924/4885TP53 4860/4885 |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | KDM1A 1318/4885ALDH1A1 1924/4885TP53 4860/4885 |
| US-20200078368-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | KDM1A 1318/4885ALDH1A1 1924/4885TP53 4860/4885 |
| US-10272094-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | KDM1A 1318/4885ALDH1A1 1924/4885TP53 4860/4885 |
| US-20200383993-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | KDM1A 1318/4885ALDH1A1 1924/4885TP53 4860/4885 |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | KDM1A 1318/4885ALDH1A1 1924/4885TP53 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.